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formation of a sequestration complex
 
Ji Luo,
 
1,2
 
 Seth J. Field,
 
1,2,3
 
 Jennifer Y. Lee,
 
1,2
 
 Jeffrey A. Engelman,
 
1,2,4
 
 and Lewis C. Cantley
 
1,2
 
1
 
Department of Systems Biology, Harvard Medical School, and 
 
2
 
Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA 02115
 
3
 
Division of Endocrinology and 
 
4
 
Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA 02114
 
hosphoinositide (PI) 3-kinase is required for most in-
sulin and insulin-like growth factor
 
 
 
(IGF) 1–depen-
dent cellular responses. The p85 regulatory subunit
of PI 3-kinase is required to mediate the insulin-dependent
recruitment of PI 3-kinase to the plasma membrane, yet
mice with reduced p85 expression have increased insulin
sensitivity. To further understand the role of p85, we ex-
amined IGF-1–dependent translocation of p85
 

 
 by using
a green fluorescence protein (GFP)–tagged p85
 

 
 (EGFP–
p85
 

 
). In response to IGF-1, but not to PDGF signaling,
EGFP–p85
 

 
 translocates to discrete foci in the cell. These
P
 
foci contain the insulin receptor substrate (IRS) 1 adaptor
molecule, and their formation requires the binding of p85
to IRS-1. Surprisingly, monomeric p85 is preferentially lo-
calized to these foci compared with the p85–p110 dimer,
and these foci are not sites of phosphatidylinositol-3,4,5-
trisphosphate
 
 
 
production. Ultrastructural analysis reveals
that p85–IRS-1 foci are cytosolic protein complexes de-
void of membrane. These results suggest a mechanism of
signal down-regulation of IRS-1 that is mediated by
monomeric p85 through the formation of a sequestration
complex between p85 and IRS-1.
 
Introduction
 
In response to growth factors, class I
 
A
 
 phosphoinositide (PI)
3-kinases generate the phospholipid second messengers phos-
phatidylinositol-3,4,5-trisphosphate (PIP
 
3
 
) and phosphatidyl-
inositol-3,4-bisphosphate (PI-3,4-P
 
2
 
; for review see Cantley,
2002). These lipids, in turn, activate a number of signaling
molecules by binding to their pleckstrin homology (PH) do-
mains. The serine–threonine protein kinase Akt is a major
downstream target of PI 3-kinase. The PH domain of Akt spe-
cifically recognizes PIP
 
3
 
 and PI-3,4-P
 
2
 
 (James et al., 1996;
Franke et al., 1997) upon recruitment to the plasma membrane,
and Akt is activated by the phosphorylation of threonine-308 in
its activation loop and by serine-473 at its COOH terminus
(Alessi et al., 1997; for review see Chan and Tsichlis, 2001).
Several lipid phosphatases, notably phosphatase and tensin ho-
mologue and SH2 domain–containing inositol phosphatase,
act to rapidly degrade PIP
 
3
 
 and, hence, terminate signaling
through this pathway (Cantley and Neel, 1999; Rohrschneider
et al., 2000).
Class I
 
A
 
 PI 3-kinase is a heterodimer consisting of a regu-
latory subunit (p85) and a catalytic subunit (p110). The p85
regulatory subunit stabilizes the p110 catalytic subunit and
holds it in a low activity state (Yu et al., 1998b). The p85 regu-
latory subunit contains two Src homology (SH) 2 domains that
recognize phosphotyrosine residues in the context pYxxM (pY,
phosphotyrosine; x, any amino acid) on activated receptors or
their adaptor molecules (Songyang et al., 1993). The binding of
p85 to tyrosine-phosphorylated proteins serves both to relieve
inhibition on the p110 catalytic subunit as well as to recruit PI
3-kinase from the cytosol to the plasma membrane, where its
substrate, PI-4,5-P
 
2
 
, resides (Rordorf-Nikolic et al., 1995).
Mammals contain three different genes for the p85 regulatory
subunit (p85
 

 
, p85
 

 
, and p55
 

 
) and three different genes for
the class I
 
A
 
 catalytic subunit (p110
 

 
, p110
 

 
, and p110
 

 
). The
major p85 isoform p85
 

 
 also exists as two shorter splice vari-
ants (p55
 

 
 and p50
 

 
) that lack the NH
 
2
 
-terminal SH3 and
RhoGAP homology domains of p85
 

 
 (Fruman et al., 1998).
Both the insulin receptor and the highly homologous insu-
lin-like growth factor (IGF) 1 receptor activate class I
 
A
 
 PI
3-kinase indirectly through phosphorylation of the insulin recep-
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3
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tor substrate (IRS) family of adaptor molecules. These recep-
tors phosphorylate tyrosine residues on IRS to create p85-bind-
ing sites (for review see Butler et al., 1998; Virkamaki et al.,
1999). PI 3-kinase is a key mediator of metabolic signaling down-
stream of the insulin receptor, and it also mediates cell differen-
tiation, survival, and proliferation downstream of both insulin
and IGF-1 receptors (Dufourny et al., 1997; Kulik et al., 1997;
Saltiel and Kahn, 2001; Tureckova et al., 2001). Despite the key
role PI 3-kinase plays in mediating glucose uptake downstream
of the insulin receptor, mice lacking various isoforms of the
p85
 

 
 or p85
 

 
 subunit of PI 3-kinase demonstrated the paradoxi-
cal phenotype of increased insulin sensitivity, which was caused
by improved PI 3-kinase signaling downstream of IRS proteins
(Terauchi et al., 1999; Fruman et al., 2000; Mauvais-Jarvis et al.,
2002; Ueki et al., 2002b; Chen et al., 2004). It was subsequently
shown that the molecular balance between monomeric p85 and
the p85–p110 dimer can influence the extent of PI 3-kinase sig-
naling downstream of the insulin receptor, as monomeric p85
can negatively regulate PI 3-kinase signaling by competing with
the p85–p110 dimer for IRS binding (Ueki et al., 2002a, 2003).
Recently, it was also reported that the protein SOCS-6 can se-
lectively bind to monomeric p85 and that overexpression of
SOCS-6 improves insulin signaling in vivo (Li et al., 2004).
Furthermore, the expression of the human placental hormone in
transgenic mice results in the up-regulation of p85 and subse-
quent insulin resistance in muscle (Barbour et al., 2004). These
lines of evidence suggest that monomeric p85 acts as a negative
regulator of insulin signaling in vivo by controlling the extent of
PI 3-kinase activation downstream of the receptor.
In this study, we have investigated the spatial transloca-
tion of the p85 regulatory subunit of PI 3-kinase in response to
IGF-1 receptor activation. We find that 5–10 min after IGF-1
stimulation, p85 and IRS-1 assemble into large complexes
(foci) in the cytosol. This complex formation appears to be
driven preferentially by monomeric p85 rather than by p85–
p110, and these complexes do not appear to be sites of PI-P
 
3
 
production. These results indicate a novel mechanism for limit-
ing IRS-1/PI 3-kinase signaling that could explain why insulin/
IGF-1 signaling is acutely sensitive to p85 levels.
 
Results
 
EGFP–p85
 

 
 translocates to discrete foci 
in response to IGF-1 signaling
 
To explore the possibility that different growth factor receptors
may result in the distinct spatial recruitment of PI 3-kinase, we
generated an EGFP-tagged p85
 

 
 chimera (EGFP–p85
 

 
; Fig.
1 A) that allowed us to visualize its localization in live cells us-
ing fluorescence video microscopy. When expressed in CHO-K1
cells at levels comparable with endogenous p85, this fusion
protein behaved similarly to endogenous p85, as judged both
by its ability to bind the p110 catalytic subunit and by its ability
to bind tyrosine-phosphorylated IRS-1 adaptor protein after
IGF-1 receptor activation (Fig. 1 B). Previous studies have
shown that when overexpressed in cells, p85 inhibits PI
3-kinase signaling (Rameh et al., 1995; Ueki et al., 2000). In
agreement with these studies, we found that the EGFP–p85
 

 
construct, when overexpressed in CHO-K1 cells at levels com-
parable with endogenous p85, significantly attenuated IGF-1–
induced Akt activation (Fig. 1 C).
In serum-starved cells, EGFP–p85
 

 
 localized diffusely in
the cytoplasm and to membrane protrusions that have been at-
tributed to focal adhesions in a previous study (Gillham et al.,
1999). Because CHO-K1 cells express both IGF-1 and PDGF
receptors endogenously, we first compared the recruitment of
EGFP–p85
 

 
 downstream of IGF-1 and PDGF receptors. Upon
stimulation with IGF-1, EGFP–p85
 

 
 was recruited to distinct
foci within 5–10 min (Fig. 2 A and Video 1, available at http://
www.jcb.org/cgi/content/full/jcb.200503088/DC1). Both low
(1 nM) and high (20 nM) concentrations of IGF-1 induced the
formation of EGFP–p85 foci in a similar fashion, although at
the lower threshold of IGF-1 (1 nM), some cells failed to re-
spond. Curiously, we did not observe significant global recruit-
Figure 1. Biochemical characterization of EGFP–p85 reporter constructs.
(A) Schematic representation of EGFP–p85 constructs with the domains
illustrated (P, proline-rich region). EGFP was fused to the NH2 terminus of
p85. The R/A (arginine to alanine) mutations in the conserved FLVRD/E
motif of both SH2 domains of p85 are also indicated. (B) CHO-K1 cells
transfected with either the wild-type EGFP–p85 or the SH2 domain mutant.
EGFP–p85 RARA (which harbors the R358A and R649A point mutations
in the SH2 domains) constructs were serum starved and stimulated with
10 nM IGF-1 for 10 min. The levels of EGFP–p85 and endogenous p85
in total cell lysate, p110 immunoprecipitate, and IRS-1 immunoprecipi-
tate were probed with anti-p85 antibody. (C) CHO-K1 cells cotransfected
with HA-Akt and EGFP–p85 or with HA-Akt and EGFP–p85 RARA were
serum starved and stimulated with 10 nM IGF-1 for 2 or 20 min. Phos-
phorylation of HA-Akt was assessed by anti–phospho-Akt threonine-308
Western blot analysis of HA immunoprecipitate. Results shown are repre-
sentative of two experiments.
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ment of EGFP–p85
 

 
 to the plasma membrane in response to
IGF-1 stimulation, suggesting that only a very small amount of
p85 (and hence PI 3-kinase) may be present at the membrane at
any given moment. On the other hand, PDGF stimulation re-
sulted in transient, weak recruitment of EGFP–p85
 

 
 to plasma
membrane patches and ruffles (Fig. 2 B and Video 2, available
at http://www.jcb.org/cgi/content/full/jcb.200503088/DC1). In
addition, IGF-1 could induce EGFP–p85
 

 
 foci formation in
cells that were previously stimulated by high concentrations of
PDGF (Fig. 2 C). This suggests that the activation of different
growth factor receptors leads to a different spatial translocation
of EGFP–p85
 

 
. Such differences in the spatial recruitment of
EGFP–p85
 

 
 are not simply a result of the difference in the sig-
naling strength of these receptors. Using antibodies against
phosphorylated Akt (i.e., activated Akt) as a readout for PI
3-kinase activation, we found that both IGF-1 and PDGF acti-
vated PI 3-kinase in these cells (Fig. 2 D). Furthermore, al-
though PDGF at 20 nM activated PI 3-kinase more strongly than
IGF-1 did at 1 nM, PDGF at 20 nM did not cause EGFP–p85
 

 
translocation to foci, whereas IGF-1 at 1 nM did.
We further explored the time course of IGF-1–dependent
EGFP–p85
 

 
 foci formation. EGFP–p85
 

 
 foci were not detect-
able until 2–5 min after IGF-1 stimulation, and their fluorescence
intensities reached maximum and stabilized within 10–20 min.
In the continuous presence of IGF-1, these foci were stable
structures that persisted in the cell, and, over time, some pro-
ceeded to fuse with each other (Fig. S1 B, available at http://
www.jcb.org/cgi/content/full/jcb.200503088/DC1). On the other
hand, withdrawing IGF-1 caused the majority of EGFP–p85
 

 
foci to disappear within 1 h (Fig. S1 C), suggesting that mainte-
nance of the EGFP–p85
 

 
 foci requires the presence of the acti-
vated IGF-1 receptor. The translocation of EGFP–p85
 

 
 to foci
downstream of IGF-1 receptors was not unique to CHO-K1
cells, as it was also observed in NIH3T3 cells (Fig. S2 A, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200503088/DC1).
Furthermore, a reporter construct for p85
 

 
 (EYFP-p85
 

 
) dem-
onstrated similar behavior to EGFP–p85
 

 
 (Fig. S2 B). As EGFP
itself can form weak dimers (for review see Zacharias, 2002), we
also performed immunofluorescence staining against FLAG-
tagged p85
 

 
 and observed similar translocation within 20 min of
IGF-1 stimulation (see Fig. 3 D). Therefore, the localization of
EGFP–p85
 

 
 to foci is not a result of EGFP moiety.
 
EGFP–p85
 

 
 foci are complexes of p85 
and tyrosine-phosphorylated IRS-1
 
Like the insulin receptor, the IGF-1 receptor activates PI
3-kinase through tyrosine phosphorylation of the IRS family of
adaptor molecules, with IRS-1 being the best-characterized
member (White, 1998). The pYxxM motifs on IRS-1 directly
bind to the SH2 domains of p85 to recruit the p85–p110 com-
plex (Backer et al., 1992; for review see Butler et al., 1998).
Therefore, we tested whether the translocation of EGFP–p85
 

 
to foci that are downstream of the IGF-1 receptor requires its
interaction with IRS-1. An arginine residue in the conserved
FLVRD/E motif of the p85 SH2 domains is critical for coordi-
nating the phosphate moiety of phosphotyrosine (Nolte et al.,
1996). Mutations of this arginine to alanine in each of the p85
SH2 domains have been shown to abolish binding to phospho-
tyrosine without affecting their overall folding (Yu et al.,
1998a). Thus, we introduced the same mutations (R358A and
R649A in the FLVRD/E motif of each of the SH2 domains of
p85
 

 
) to generate the EGFP–p85
 

 
 RARA mutant. As expected,
although this mutant bound the PI 3-kinase p110 catalytic sub-
unit normally, it could no longer bind tyrosine-phosphorylated
IRS-1 after IGF-1 stimulation (Fig. 1 B). Furthermore, the
EGFP–p85
 

 
 RARA mutant was much less effective at inhibiting
Akt activation when overexpressed in cells (Fig. 1 C), indicating
that functional SH2 domains are required for the inhibition of PI
3-kinase signaling by p85. When we coexpressed the CFP-
tagged mutant ECFP-p85 RARA with the YFP-tagged wild-
type EYFP-p85 in the same cell, only the wild-type EYFP-p85
translocated to foci in response to IGF-1, whereas the SH2 do-
main mutant ECFP-p85 RARA did not (Fig. 3 A). This indi-
cates that the SH2 domains of p85 are essential in mediating
such translocation.
Conversely, we asked whether IRS-1 is also present at the
EGFP–p85
 

 
 foci. Immunofluorescence staining against endog-
enous IRS-1 revealed that it colocalized to the EGFP–p85
 

 
foci after IGF-1 stimulation (Fig. 3 B). Interestingly, the local-
ization of endogenous IRS-1 to foci was more prominent in
cells that also expressed EGFP–p85
 

 
, suggesting that the mod-
est amount of EGFP–p85
 

 
 expressed in these cells promotes
Figure 2. IGF-1, but not PDGF, induces the translocation of EGFP–p85
to foci. (A–C) CHO-K1 cells stably expressing EGFP–p85 were serum
starved and stimulated with 1 nM IGF-1 (A), 20 nM PDGF (B), or first with
20 nM PDGF for 15 min followed by 1 nM IGF-1 for an additional 15 min
(C). Cells were imaged live, and frames at indicated time points are
shown. Arrowhead indicates PDGF-induced transient EGFP–p85 patches
(Videos 1 and 2, available at http://www.jcb.org/cgi/content/full/
jcb.200503088/DC1). Results shown are representative of at least five ex-
periments. (D) CHO-K1 cells were serum starved and stimulated with either
PDGF or IGF-1 at indicated concentrations for 10 min. Total cell lysates
were probed with anti–phospho-Akt serine-473 antibody to assess the level
of Akt activation. Results shown are representative of two experiments.
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the recruitment of IRS-1 to these foci. Tyrosine phosphoryla-
tion of IRS-1 is also critical for the localization of IRS-1 to
these foci. When we coexpressed EGFP–p85
 

 
 with a mutant
IRS-1 that had six tyrosine residues mutated to phenylalanine
(IRS-1–F6) and, hence, was impaired in PI 3-kinase binding
(Esposito et al., 2001), this IRS-1–F6 mutant was also impaired
in its ability to localize to EGFP–p85
 

 
 foci (Fig. 3 C). These
results suggest that tyrosine phosphorylation of IRS-1 and its
binding to p85 is required for the recruitment of IRS-1 into
these foci.
To rule out the possibility that only overexpressed p85
 

 
that is additional to endogenous p85 proteins can form such
foci with IRS-1, we expressed EGFP–p85
 

 
 and p85
 

 
-FLAG in
mouse embryonic fibroblasts (MEFs) that were null for both
the p85
 

 
 and p85
 

 
 genes (Brachmann et al., 2005b). We ob-
served IGF-1–induced p85
 

 
 foci formation in p85
 

 

 
/
 

 
p85
 

 

 
/
 

 
MEFs expressing even the lowest detectable levels of p85
 

 
proteins. Furthermore, the introduction of FLAG-tagged p85
 

 
into p85
 

 

 
/
 

 
p85
 

 

 
/
 

 
 MEFs by retrovirus infection (using con-
ditions that we have previously shown to result in exogenous
p85
 

 
 levels similar to or lower than endogenous p85
 

 
 of wild-
type MEFs; Brachmann et al., 2005b) led to p85
 
 foci in re-
sponse to IGF-1 (Fig. 3 D). Thus, p85–IRS-1 foci appear in
response to IGF-1 in cells in which total p85 is at or below
endogenous levels.
Interestingly, we found that the shorter isoform p55,
which lacks the NH2-terminal SH3 and RhoGAP homology do-
mains of p85, did not translocate to foci in response to IGF-1
(Fig. 3 E). A similar result was obtained with the other shorter
isoform p50 (unpublished data). This suggests that SH3 and/
Figure 3. EGFP–p85 foci consist of both p85 and IRS-1. (A) CHO-K1 cells cotransfected with wild-type EYFP-p85 and SH2-domain mutant ECFP-p85
RARA were serum starved and stimulated with 10 nM IGF-1. Cells were imaged live in both the yellow and cyan fluorescence channels. Frames at the in-
dicated time points are shown. (B) CHO-K1 cells stably expressing EGFP–p85 were serum starved and stimulated with 10 nM IGF-1 for 20 min. Cells
were fixed, and endogenous IRS-1 was visualized with anti–IRS-1 immunofluorescence. (right) Merged image illustrates the colocalization of EGFP–p85
and anti–IRS-1 staining. (C) CHO-K1 cells cotransfected with EGFP–p85 and HA-tagged wild-type IRS-1 or mutant IRS-1–F6 constructs were serum starved
and stimulated with 10 nM IGF-1 for 20 min. IRS-1 was visualized with anti-HA immunofluorescence. Results shown are representative of three experiments.
(D) p85p85 MEFs either transiently expressing EGFP–p85 (left) or p85-FLAG (middle) or retrovirally expressing p85-FLAG (right) were starved
and stimulated with 10 nM IGF-1 for 20 min. Cells were fixed, and the localization of p85 was either directly visualized (EGFP–p85) or was visual-
ized by anti-FLAG immunofluorescence (p85-FLAG). (E) CHO-K1 cells expressing FLAG-tagged p85 or p55 were serum starved and stimulated with
10 nM IGF-1 for 20 min. The localization of p85-FLAG or p55-FLAG was visualized by anti-FLAG immunofluorescence. Representative images of two
experiments are shown.
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or RhoGAP homology domains of p85 play a role in its local-
ization to these foci.
EGFP–p85–IRS-1 complexes are sites of 
IRS-1 sequestration
We next investigated whether these EGFP–p85–IRS-1 foci
are sites of PIP3 production. We first used Akt–PH domain–
EGFP fusion protein as a reporter to detect PIP3 production in
the cell (Gray et al., 1999). We were able to improve the sen-
sitivity of this reporter by trimerizing the PH domain (EGFP-
[3]AktPH). As expected, EGFP-(3)AktPH translocated to the
plasma membrane in response to stimulation by growth fac-
tors, whereas an analogous construct bearing an R25C muta-
tion in each of the PH domains that abolishes binding to the 3
phosphate of PIP3 (Varnai et al., 1999) failed to do so (Fig. S3,
available at http://www.jcb.org/cgi/content/full/jcb.200503088/
DC1). In addition, the membrane translocation of EGFP-
(3)AktPH was also blocked by the PI 3-kinase inhibitor wort-
mannin (unpublished data). After IGF-1 stimulation, EGFP-
(3)AktPH consistently translocated to plasma membrane
patches and ruffles within 1–2 min, which is a time course
that is more rapid than that of the EGFP–p85 translocation
to foci. The pattern of Akt PH domain localization was much
more diffused than that of the EGFP–p85 foci (Fig. S3).
Figure 4. EGFP–p85 foci are not the sites of PIP3 production. (A) CHO-K1 cells cotransfected with EYFP-p85 and ECFP-(3)AktPH constructs were serum
starved and stimulated with 10 nM IGF-1. Cells were imaged live in both the yellow and cyan fluorescence channels. Frames at 10 min post–IGF-1 stimu-
lation are shown. (B) The fluorescence intensity in A was profiled to show the lack of colocalization between the signal of EYFP-p85 (green) and that of
ECFP-(3)AktPH (red). Results shown are representative of three experiments. (C) CHO-K1 cells stably expressing EGFP–p85 were serum starved and stim-
ulated with 10 nM IGF-1 for the indicated periods of time. The levels of tyrosine-phosphorylated IRS-1, EGFP–p85, and p85 that bound to IRS-1 and
serine-473–phosphorylated Akt on Western blots were quantified and normalized to their respective levels at the 10-min time point. A representative blot
is shown in the inset. At each time point, the percentage of cells that harbor EGFP–p85 foci were also counted. Data represent mean  SEM of three ex-
periments (#, P 	 0.01; ‡, P 	 0.08; compared with IRS-1–bound p85 levels at the same time point). (D) CHO-K1 cells cotransfected with EGFP–p85
and HA-tagged p110 were serum starved and stimulated with 10 nM IGF-1 for 20 min. p110 was visualized with anti-HA immunofluorescence. The right
panel shows the merged image. Arrow, focal adhesion-like structure; arrowhead, EGFP–p85 focus. Results shown are representative of three experiments.
(E) CHO-K1 cells transfected with EGFP–p85 alone or with EGFP–p85 and HA-tagged p110 were serum starved and stimulated with 10 nM IGF-1
for 20 min. The number of transfected cells that also contained EGFP–p85 foci were counted. Results shown are mean  SEM from three experiments.
(F) CHO-K1 cells were serum starved and stimulated with 10 nM IGF-1 for either 2 or 20 min. The levels of endogenous p85 and p110 in IRS-1 immuno-
precipitate were assessed by Western blotting (left) and quantified by densitometry (right). The relative levels of p85 and p110 at each time point was
calculated by normalizing against their respective values at the 2-min time point. Results shown are mean  SEM from three experiments.
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When EYFP-p85 and ECFP-(3)AktPH were coexpressed in
the same cell and imaged simultaneously, the translocation of
the ECFP-(3)AktPH domain to the plasma membrane was of-
ten found to be suppressed (unpublished data), again indicat-
ing the down-regulation of PI 3-kinase signaling by p85. In
cells in which ECFP-(3)AktPH did show detectable mem-
brane translocation, ECFP-(3)AktPH patches did not colocal-
ize with the EYFP-p85 foci (Fig. 4, A and B), suggesting
that these EYFP-p85 foci are not the sites of PIP3 pro-
duction. This conclusion is further supported by the observa-
tion that IRS-1 phosphorylation, PI 3-kinase activation, and
Akt activation precedes the appearance of EGFP–p85 foci
in CHO-K1 cells. As shown in Fig. 4 C, 90% of maximum
tyrosine phosphorylation on IRS-1 occurred within the
first minute after IGF-1 stimulation. The recruitment of PI
3-kinase to IRS-1 was equally rapid with a nearly identical
time course. It took 2 min, however, for the majority of Akt
to become activated; this short delay presumably reflects the
time required for PI 3-kinase to generate PIP3 at the plasma
membrane. Furthermore, there was an 5-min delay before
most cells were observed to harbor EGFP–p85 foci. The ac-
tivation of Akt, therefore, precedes the formation of EGFP–
p85 foci.
Direct localization of the p110 catalytic subunit of PI
3-kinase by using a COOH-terminal HA-tagged p110 gave us
a surprising result: although it colocalized with EGFP–p85
to focal adhesion-like structures in quiescent cells, it did not
colocalize to the EGFP–p85 foci after IGF-1 stimulation
(Fig. 4 D). This result suggests that only free, monomeric
p85, but not p110-bound p85, is able to translocate to the
foci. Indeed, the fraction of cells harboring EGFP–p85 foci
upon IGF-1 stimulation was reduced from 90 to 60% when
p110 was coexpressed with EGFP–p85 (Fig. 4 E). This re-
sult also explains the observation that the localization of IRS-1
to foci is more prominent in cells expressing EGFP–p85, pre-
sumably because even modest overexpression of EGFP–p85
significantly increases the relative level of p85 monomer
to p85–p110 dimer. Altogether, these results suggest that
EGFP–p85 foci contain primarily monomeric p85 but not
p85–p110 dimer, and that they are not a site of PI 3-kinase
signaling. These observations suggest that p85–IRS-1 foci
may actually serve to down-regulate PI 3-kinase signaling by
sequestering tyrosine-phosphorylated IRS-1 and, hence, limit
its recruitment of the p85–p110 dimer. Indeed, when we as-
sessed the amount of endogenous p85 and p110 that is associ-
ated with IRS-1 at either 2 min (before foci formation) or 20
min (after foci formed) after IGF-1 stimulation, we found that
the level of IRS-1–bound p110 at 20 min post–IGF-1 stimu-
lation was only 33% of that at 2 min. In contrast, the levels of
IRS-1–bound p85 remained essentially unchanged (Fig. 4 F).
Thus, the molecular balance between IRS-1–associated p110
and p85 has shifted from the p85–p110 dimer to the p85
monomer with a time frame comparable with that of EGFP–
p85–IRS-1 foci formation.
Figure 5. EGFP–p85 foci are intracellular
protein complexes. (A) CHO-K1 cells stably
expressing EGFP–p85 were serum starved
and stimulated with 10 nM IGF-1. Cells were
imaged live under TIRFM, and frames of the
indicated time points are shown. Arrowhead,
focal adhesion-like structure. Results shown
are representative of three experiments. (B)
Same experiment as in A; the internalization
of one of the EGFP–p85 foci (arrow) away
from the field of view of TIRFM was captured
at the indicated time frames. Thereafter, the il-
lumination was immediately switched from
TIRFM to epifluorescence to show that the
same spot was still visible under epifluores-
cence microscopy. (C) CHO-K1 cells stably
expressing EGFP–p85 were serum starved
and stimulated with IGF-1 for 60 min. Endoge-
nous EEA1 protein was visualized with anti-
EEA1 immunofluorescence. Similar results
were obtained when cells were stimulated
with IGF-1 for 10 or 30 min. Results shown
are representative of three experiments. (D)
CHO-K1 cells stably expressing EGFP–p85
were serum starved and stimulated with IGF-1
for 10 min. Endogenous caveolin-1 protein
was visualized with anti–caveolin-1 immuno-
fluorescence. Similar results were obtained
when cells were stimulated with IGF-1 for 30
or 60 min. Results shown are representative of
three experiments. (E) CHO-K1 cells stably ex-
pressing EGFP–p85 were serum starved and
stimulated with IGF-1 for 20 min. EGFP–p85
was immunogold stained and visualized with
transmission EM (PM, plasma membrane; M,
mitochondrion; arrow, one EGFP–p85 focus). (F) A proposed model of the sequestration of IRS-1 by monomeric p85 as a means to negatively regulate
PI 3-kinase signaling. P, phosphorylation on tyrosine residues.
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EGFP–p85–IRS-1 complexes are 
cytosolic protein complexes
Previous studies in 3T3-L1 cells have suggested that IRS-1 and
p85 are selectively enriched in intracellular membrane fractions
after insulin stimulation (Nave et al., 1996; Inoue et al., 1998).
To determine the subcellular localization and structural nature
of EGFP–p85 foci, we first assessed their membrane prox-
imity with total internal reflection fluorescence microscopy
(TIRFM) to visualize EGFP–p85 that was within 100 nm of
the plasma membrane (Toomre and Manstein, 2001). Interest-
ingly, as with epifluorescence microscopy, we did not observe
prominent global translocation of EGFP–p85 to the plasma
membrane upon IGF-1 stimulation. TIRFM revealed that many
of the EGFP–p85 foci formed near the plasma membrane
(Fig. 5 A and Video 3, available at http://www.jcb.org/cgi/
content/full/jcb.200503088/DC1). Once formed, however, many
foci internalized away from the plasma membrane as they be-
came invisible under TIRFM, whereas they were still visible
under epifluorescence microscopy (Fig. 5 B).
Signaling through the IGF-1 receptor (as well as through
the insulin receptor) has been shown to be regulated by en-
docytosis via clathrin-coated vesicles as well as by caveolae
(Chow et al., 1998; Rotem-Yehudar et al., 2001; Huo et al.,
2003). Our observations that EGFP–p85 foci were not the
sites of PIP3 production and could internalize away from the
plasma membrane suggest that such foci may be endocytotic
vesicles, which prompted us to examine whether EGFP–p85
foci represent either early endosomes or caveolae. Immunofluo-
rescence staining revealed that EGFP–p85 foci did not colocal-
ize with the early endosome marker EEA1 even after extended
incubation with IGF-1 (Fig. 5 C). Similarly, using immuno-
fluorescence staining against caveolin-1 as a marker for cave-
olae, we found that EGFP–p85 foci also did not colocalize
with caveolin-1 (Fig. 5 D). Both the actin cytoskeleton and PI
3-kinase itself have been implicated in the regulation of endocy-
tosis and endosomal trafficking (Joly et al., 1995; Engqvist-
Goldstein and Drubin, 2003). Neither the PI 3-kinase inhibitor
wortmannin nor the actin-depolymerizing agent latrunculin B
or the microtubule-destabilizing agent nocodazole, however,
had any effect on the formation of EGFP–p85 foci (unpub-
lished data). Thus, these results indicate that EGFP–p85 foci
are unlikely to be endocytotic vesicles. Next, we determined
the ultrastructure of EGFP–p85 foci by immunogold EM. In
unstimulated cells, immunogold staining against EGFP–p85
was diffuse in the cytoplasm (unpublished data). In IGF-1–
stimulated cells, clusters of staining were observed in elec-
tron-dense structures 100–200 nm in diameter that resided in
the cytoplasm (Fig. 5 E). These structures are likely to be pro-
tein complexes rather than vesicles because they were not delim-
ited with lipid bilayers and there was no exclusion of staining
from the center of these structures.
Discussion
The p85 regulatory subunit of class IA PI 3-kinase is essential
for both the stability of the p110 catalytic subunit (Yu et al.,
1998a,b) and its recruitment to activated growth factor receptors
or adaptor molecules (Cantley, 2002). Therefore, it was a sur-
prise that mice lacking the various p85 regulatory subunits
actually showed improved insulin signaling and enhanced in-
sulin-stimulated Akt activation (Terauchi et al., 1999; Fruman
et al., 2000; Ueki et al., 2002b; Chen et al., 2004). This paradox
was, in part, reconciled by the observation that the p85 regula-
tory subunit is in excess over the p110 catalytic subunit in many
cell types and that monomeric p85 competes with p85–p110
heterodimers for binding to IRS proteins (Ueki et al., 2002a,b,
2003; Brachmann et al., 2005a). This competitive binding
model (Fig. 5 F) could explain why deleting a subset of p85 reg-
ulatory genes (homozygous deletion of p85, heterozygous de-
letion of p85, or deletion of specific alternative splice variants
of p85), which leads to reduced levels of monomeric p85 with
little effect on p85–p110 heterodimers, ultimately results in en-
hanced binding of p85–p110 PI 3-kinase to IRS proteins and in-
creased insulin sensitivity (Mauvais-Jarvis et al., 2002; Ueki et
al., 2002b; Chen et al., 2004). However, this model fails to ex-
plain why the homozygous deletion of all splice variants of
p85 also results in increased insulin sensitivity (Fruman et al.,
2000). Insulin-sensitive tissues from these mice have dramati-
cally lower levels of PI 3-kinase activity as a result of a reduction
in all forms of class IA p85–p110 enzymes. As a consequence,
less PI 3-kinase activity is recruited to IRS proteins 5 min after
insulin stimulation. However, glucose clearance from the serum
is dramatically enhanced, and serum insulin levels are lower.
These results indicate that monomeric p85 protein plays a nega-
tive role in insulin signaling that is more complex than simple
competition with p85–p110 for binding to IRS-1.
In the current study, by using EGFP–p85 as a reporter
for the localization of p85 in live cells, we found that IGF-1 re-
ceptor activation induces the translocation of EGFP–p85 to
distinct, foci-like complexes that contain p85 bound to ty-
rosine-phosphorylated IRS-1 (Figs. 2 and 3). The interaction
between p85 and IRS-1 is critical for the dominant negative ef-
fect of monomeric p85, as the SH2 domain–mutated p85 that
fails to bind IRS-1 and form foci is far less effective at inhibit-
ing PI 3-kinase signaling (Fig. 1, B and C). Surprisingly, these
complexes contain primarily monomeric p85 with less of the
p85–p110 dimer and appear to be protein-only complexes that
are devoid of membrane components. Because these com-
plexes are not on the membrane, the enzyme would not have
access to its lipid substrate even if some p85–p110 dimer was
present in the complex (Figs. 4 and 5). These observations sug-
gest a novel mechanism to explain how monomeric p85 inhib-
its PI 3-kinase signaling downstream of IRS-1 (Fig. 5 F). In
this modified model, in addition to being a competitive inhibi-
tor for p85–p110 binding to IRS-1, monomeric p85 sequesters
IRS-1 in cytosolic protein complexes and renders it incapable
of stimulating PIP3 production. The failure to form these se-
questration complexes in mice lacking all isoforms of p85
(Fruman et al., 2000) would explain why insulin signaling in
these animals is more efficient even though less PI 3-kinase is
present. As the absence of monomeric p85 would eliminate the
sequestration of IRS-1, this allows the small amount of p85–
p110 dimers that form complexes with IRS-1 to efficiently
signal for a longer period of time.
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The two mechanisms of negative regulation by mono-
meric p85 (competitive binding vs. sequestration) are likely to
operate in concert to limit both the amplitude and duration of
PI 3-kinase signaling downstream of IRS-1. The competitive
binding of monomeric p85 for IRS-1 modulates the amplitude
of PI 3-kinase signaling at early time points (e.g., 1–2 min) af-
ter IGF-1 stimulation, whereas the sequestration of IRS-1 by
p85 in a nonsignaling complex at later time points (10–20 min)
serves to limit the duration (and possibly the overall amplitude)
of PI 3-kinase signaling. In comparison to the competitive
binding model, the sequestration model displays two additional
properties that make it an attractive mechanism for signal
down-regulation. First, the formation of the p85–IRS-1 com-
plex occurs with a 5–10-min time delay (Fig. S1 A), thus al-
lowing IRS-1 a short window of time to recruit and activate
p85–p110 PI 3-kinase (which occurs within 1 min of receptor
ligation; Fig. 4 C); thereafter, the sequestration of IRS-1 would
rapidly attenuate the signal. Furthermore, as the p85–IRS-1
complexes persist for an extended period of time after IGF-1
withdrawal (30 min–1 h; Fig. S1 C), they could also serve as a
mechanism of recalcitrance to subsequent IGF-1 or insulin
stimulation. Second, the sequestration model provides a mech-
anism by which a small amount of monomeric p85 could have
a profound impact on PI 3-kinase signaling, as a relatively
small change in the monomeric p85 level could lead to a rela-
tively large change in the amount of tyrosine-phosphorylated
IRS-1 that is available to recruit the p85–p110 dimer.
Existing antibodies to p85 localize to foci-like structures
in a number of cell types. However, these antibodies also detect
foci-like structures in p85p85 fibroblasts, hence pre-
cluding their specificity towards p85 in immunofluorescence
staining. Although we were unable to identify a p85 antibody
that was suitable for the localization of endogenous p85 by im-
munofluorescence, it is likely that endogenous, monomeric p85
also forms sequestration complexes with IRS-1 in response to
IGF-1 or insulin signaling. Low levels of p85 expression
alone in p85p85 MEFs that completely lacked endog-
enous p85 proteins were sufficient for IGF-1–induced p85–
IRS-1 foci (Fig. 3 D), suggesting that such complex formation
can occur at p85 levels close to that of endogenous p85 pro-
teins. Our biochemical analysis of the levels of IRS-1–associ-
ated endogenous p85 and p110 reveals that there is far less
p110 associated with IRS-1 at 20 min post-stimulation com-
pared with that at 2 min, whereas the amount of p85 that is as-
sociated with IRS-1 remains essentially unchanged at these
time points (Fig. 4 F). The IRS-1–associated p85/p110 ratio,
therefore, shifts toward p85 at a later time (20 min post–IGF-1
stimulation) and in temporal correlation with the appearance of
p85–IRS-1 complexes. Consistent with this model, the eleva-
tion of in vivo p85 levels (with no change in p110 levels) oc-
curs in response to placental growth hormone, which has been
shown to correlate with pregnancy-induced insulin resistance
(Barbour et al., 2004; Kirwan et al., 2004). Thus, the changes
in insulin or IGF-1 sensitivity that we observed upon manipula-
tion of the levels of p85 isoforms in mice or in cell lines are in
agreement with pathophysiological insulin resistance that occurs
in correlation with the elevation of p85 levels in vivo.
Finally, it is of interest to note that only the full-length
isoforms of p85 (p85 and p85), but not the shorter isoforms
(p55 and p50), could form complexes with IRS-1 (Fig. 3 D),
albeit p55 and p50 possess the same SH2 domains as p85.
This suggests that in addition to the SH2 domains, the NH2-ter-
minal half of p85 is also necessary for the formation of the p85–
IRS-1 complex. It has been shown that p85 can homodimerize
through its NH2-terminal SH3 and RhoGAP homology domains
(Harpur et al., 1999). This observation provides an intrigu-
ing mechanism of p85–IRS-1 complex formation. A p85 ho-
modimer would have four SH2 domains available (two on each
p85 monomer) that could, in theory, bind to various combina-
tions of at least six phosphotyrosine motifs on IRS-1. Thus, a
given p85 homodimer could bind to two or more distinct IRS-1
molecules and vice versa. This would allow the multimerization
of p85 and IRS-1 that leads to the formation of a large globular
structure, which is consistent with the EM image of the p85–
IRS-1 complex (Fig. 5 E). Alternatively, other molecules that
interact with the NH2-terminal half of p85 may be required for
the formation of the p85–IRS-1 sequestration complex.
In conclusion, we demonstrate in this study that the p85
regulatory subunit of PI 3-kinase, when in excess over the p110
catalytic subunit, can drive the formation of large complexes
that contain tyrosine-phosphorylated IRS-1 after IGF-1 receptor
ligation. The p85–IRS-1 complex localizes to the cytosol and,
thus, is not a site for PI-3,4,5-P3 production. We propose that
the formation of this complex provides a mechanism for limit-
ing insulin and IGF-1 signaling in vivo. It also offers an expla-
nation for why the elevation of p85 under pathophysiological
conditions correlates with insulin resistance, whereas the dele-
tion of p85 genes results in increased insulin sensitivity even
under conditions in which total PI 3-kinase activity is reduced.
Materials and methods
Plasmids, cell culture, antibodies, and other reagents
Mouse full-length p85 and p85 cDNA were PCR cloned into EGFP/
EYFP/ECFP-C1 vectors (CLONTECH Laboratories, Inc.) to create the GFP/
YFP/CFP-tagged p85 constructs. p85 constructs also carry a FLAG tag at
its COOH terminus. The R358A and R649A mutations in p85 were gen-
erated by sequential site-directed PCR mutagenesis. The EGFP–p85 frag-
ment was excised from the EGFP-C1-p85 plasmid and was subcloned
into the ecdysone-inducible pFR-MCS vector (R. Herzig, RHeoGene) to gen-
erate pFR-MCS-EGFP–p85. COOH-terminally tagged p85 and p55
were generated by subcloning mouse p85 and p50 into the pCMV6
vector. Retrovirus expressing tagged p85 was generated from a p85-
FLAG construct in pJP1520 retroviral vector. COOH-terminally HA-tagged
p110 was generated by PCR cloning of bovine p110 into pcDNA3 vec-
tor. Human Akt1 PH domain (aa 1–164) was PCR cloned into EGFP/
EYFP/ECFP-N1 vectors (CLONTECH Laboratories, Inc.) to create the GFP/
YFP/CFP-tagged Akt PH domain constructs. The R25C mutation in the Akt
PH domain was generated by site-directed PCR mutagenesis. Multimer-
ized Akt PH domain constructs were created by the insertion of additional
copies of the PH domains into the single Akt PH domain construct. The
plasmids pCIS2–IRS-1 and pCIS2–IRS-1–F6, which express HA-tagged
wild-type or mutant human IRS-1, respectively, were a gift from M.J. Quon
(National Institutes of Health [NIH], Bethesda, MD).
CHO-K1 cells were maintained in DME-F12 and 10% FCS with
10% CO2, whereas p85p85 MEFs were maintained in DME and
15% FCS with 10% CO2. Transient transfection was performed using Lipo-
fectAMINE Plus (Invitrogen). Stable CHO-K1 cells expressing EGFP–p85
under an ecdysone-inducible promoter were established by serial transfec-
tion of the cells first with the plasmids pEcR, pRXR, and pTK-hyg, and then
with the plasmids pSV40/Zeo2 and pFR-MCS-EGFP–p85 (RHeoGene).
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Stable clones were screened for the inducible expression of EGFP–p85
in response to the ecdysone analogue GS-E and were maintained in DME-
F12 and 10% FCS supplemented with 350 
g/ml hygromycin (GIBCO
BRL) and 400 
g/ml Zeocin (Invitrogen). The expression of EGFP–p85
was induced with 5 
M GS-E for 24–48 h.
Anti-p85 and anti-pTyr antibodies have been described previously
(Fruman et al., 2000). Anti–IRS-1 and anti-p110 antibodies were obtained
from Upstate Biotechnology; anti-EEA1 and anti–caveolin-1 antibodies were
from Transduction Laboratories; anti–phospho-Akt serine-473, anti–phos-
pho-Akt threonine-308, and anti-Akt antibodies were from Cell Signaling
Technology; anti-HA antibody was from Sigma-Aldrich; anti-EGFP antibody
was from CLONTECH Laboratories, Inc.; Texas red–conjugated secondary
antibodies were from Jackson ImmunoResearch Laboratories; and colloidal
gold-conjugated secondary antibody was from Utrecht University Medical
Center. IGF-1 and PDGF were from Austral Biologicals.
Protein immunoblotting, immunoprecipitation, and immunostaining
Cells were lysed in lysis buffer (25 mM Tris-HCl, pH 7.4, 150 mM NaCl,
10% glycerol, 1% NP-40, 1 mM EDTA, 1 mM DTT, 20 mM NaF, 10 mM
sodium pyrophosphate, 50 mM -glycerophosphate, 1 mM Na3VO4, 1 mM
PMSF, and 4 
g/ml each of leupeptin, aproteinin, and pepstatin). Clari-
fied lysate was subjected to immunoprecipitation overnight at 4C, and
the immunoprecipitate was washed three times with wash buffer (25 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 20 mM NaF, 10 mM so-
dium pyrophosphate, and 50 mM -glycerophosphate). Proteins were sep-
arated on SDS-PAGE gels and subjected to Western blotting. Quantitation
of the Western signal was performed using an imaging system (Odyssey;
LI-COR Biosciences). Immunofluorescence staining was essentially the
same as described previously (Kanai et al., 2001), as was immunogold
staining for EM (Griffiths, 1993).
Microscopy
For live cell imaging experiments, cells were maintained in phenol red–free
DME-F12 in an environment chamber on a 37C heated microscope stage.
A 10% CO2 environment was also applied for imaging experiments ex-
ceeding 1 h. IGF-1 or PDGF was directly added to the environment cham-
ber to achieve the desired final concentrations. Ligand was removed with
acid wash in some experiments (Jones and Kazlauskas, 2001). Live cell epi-
fluorescence video microscopy was performed on a microscope (Diaphot
300; Nikon) with filter sets for EGFP, EYFP, and ECFP fluorescence using a
60 oil immersion objective or a 20 objective, and images were cap-
tured with ImagePro 4 software (Media Cybernetics). Live cell TIRFM was
performed on a modified microscope (model IX70; Olympus) with a single
green laser using a 60 oil immersion objective, and images were cap-
tured with Metamorph 5 software (Universal Imaging Corp.). Immunofluo-
rescence imaging of fixed cells was performed on a confocal microscope
(model E800; Nikon/Bio-Rad Laboratories) with a dual green/red laser us-
ing a 100 oil immersion objective, and images were captured with Laser-
Sharp 2000 software (Bio-Rad Laboratories). Immunogold transmission EM
was performed on an electron microscope (model 1200EX; JEOL). Raw im-
ages were further processed by using Adobe Photoshop 7 for presentation,
and, in some cases, brightness and contrast were adjusted linearly and con-
sistently for all images within the same experiment. Videos were compiled
and annotated by using QuickTime Pro software (Apple Computer, Inc.).
Online supplemental material
Fig. S1 shows the dynamics of EGFP–p85 foci in CHO-K1 cells after IGF-1
stimulation and the subsequent removal of IGF-1. Fig. S2 shows EGFP–
p85 foci formation in NIH3T3 cells and EYFP-p85 foci formation in
CHO-K1 cells after IGF-1 stimulation. Fig. S3 shows translocation of the
EGFP-(3)AktPH reporter construct in response to IGF-1 stimulation in CHO-
K1 cells. Videos 1–3 are time-lapse videos of CHO-K1 cells expressing
EGFP–p85 that are stimulated with either IGF-1 or PDGF. Selected frames
of these videos are shown in Figs. 2 (A and B) and 5 A, respectively.
We thank Dr. Ron Herzig and Dr. Michael Quon for providing us with plas-
mids and DNA constructs, Vassilious Bezzerides and Dr. David Clapham for
assistance with TIRFM, Maria Ericcson for assistance with EM, and Dr. John
Blenis, Dr. Thomas Roberts, and Dr. Junying Yuan for discussion and advice. 
This work was supported by a Howard Hughes Medical Institute
(HHMI) Predoctoral Fellowship to J. Luo, by an HHMI Physician Postdoctoral
Fellowship and an NIH grant (K08 DK065108-01) to S.J. Field, and by NIH
grants (GM41890 and CA089021) to L.C. Cantley.
Submitted: 16 March 2005
Accepted: 20 June 2005
References
Alessi, D.R., S.R. James, C.P. Downes, A.B. Holmes, P.R. Gaffney, C.B. Reese,
and P. Cohen. 1997. Characterization of a 3-phosphoinositide-dependent
protein kinase which phosphorylates and activates protein kinase Balpha.
Curr. Biol. 7:261–269.
Backer, J.M., M.G. Myers Jr., S.E. Shoelson, D.J. Chin, X.J. Sun, M. Miralpeix,
P. Hu, B. Margolis, E.Y. Skolnik, J. Schlessinger, et al. 1992. Phosphati-
dylinositol 3-kinase is activated by association with IRS-1 during insu-
lin stimulation. EMBO J. 11:3469–3479.
Barbour, L.A., J. Shao, L. Qiao, W. Leitner, M. Anderson, J.E. Friedman, and
B. Draznin. 2004. Human placental growth hormone increases expres-
sion of the p85 regulatory unit of phosphatidylinositol 3-kinase and
triggers severe insulin resistance in skeletal muscle. Endocrinology.
145:1144–1150.
Brachmann, S.M., K. Ueki, J.A. Engelman, R.C. Kahn, and L.C. Cantley.
2005a. Phosphoinositide 3-kinase catalytic subunit deletion and regula-
tory subunit deletion have opposite effects on insulin sensitivity in mice.
Mol. Cell. Biol. 25:1596–1607.
Brachmann, S.M., C.M. Yballe, M. Innocenti, J.A. Deane, D.A. Fruman, S.M.
Thomas, and L.C. Cantley. 2005b. Role of phosphoinositide 3-kinase
regulatory isoforms in development and actin rearrangement. Mol. Cell.
Biol. 25:2593–2606.
Butler, A.A., S. Yakar, I.H. Gewolb, M. Karas, Y. Okubo, and D. LeRoith.
1998. Insulin-like growth factor-I receptor signal transduction: at the in-
terface between physiology and cell biology. Comp. Biochem. Physiol. B
Biochem. Mol. Biol. 121:19–26.
Cantley, L.C. 2002. The phosphoinositide 3-kinase pathway. Science. 296:
1655–1657.
Cantley, L.C., and B.G. Neel. 1999. New insights into tumor suppression:
PTEN suppresses tumor formation by restraining the phosphoinositide
3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA. 96:4240–4245.
Chan, T.O., and P.N. Tsichlis. 2001. PDK2: a complex tail in one Akt. Sci.
STKE. 10.1126/stke.2001.66.pe1.
Chen, D., F. Mauvais-Jarvis, M. Bluher, S.J. Fisher, A. Jozsi, L.J. Goodyear, K.
Ueki, and C.R. Kahn. 2004. p50alpha/p55alpha phosphoinositide
3-kinase knockout mice exhibit enhanced insulin sensitivity. Mol. Cell.
Biol. 24:320–329.
Chow, J.C., G. Condorelli, and R.J. Smith. 1998. Insulin-like growth factor-I re-
ceptor internalization regulates signaling via the Shc/mitogen-activated
protein kinase pathway, but not the insulin receptor substrate-1 pathway.
J. Biol. Chem. 273:4672–4680.
Dufourny, B., J. Alblas, H.A. van Teeffelen, F.M. van Schaik, B. van der Burg,
P.H. Steenbergh, and J.S. Sussenbach. 1997. Mitogenic signaling of in-
sulin-like growth factor I in MCF-7 human breast cancer cells requires
phosphatidylinositol 3-kinase and is independent of mitogen-activated
protein kinase. J. Biol. Chem. 272:31163–31171.
Engqvist-Goldstein, A.E., and D.G. Drubin. 2003. Actin assembly and endocy-
tosis: from yeast to mammals. Annu. Rev. Cell Dev. Biol. 19:287–332.
Esposito, D.L., Y. Li, A. Cama, and M.J. Quon. 2001. Tyr(612) and Tyr(632) in
human insulin receptor substrate-1 are important for full activation of in-
sulin-stimulated phosphatidylinositol 3-kinase activity and translocation
of GLUT4 in adipose cells. Endocrinology. 142:2833–2840.
Franke, T.F., D.R. Kaplan, L.C. Cantley, and A. Toker. 1997. Direct regulation of
the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate.
Science. 275:665–668.
Fruman, D.A., R.E. Meyers, and L.C. Cantley. 1998. Phosphoinositide kinases.
Annu. Rev. Biochem. 67:481–507.
Fruman, D.A., F. Mauvais-Jarvis, D.A. Pollard, C.M. Yballe, D. Brazil, R.T.
Bronson, C.R. Kahn, and L.C. Cantley. 2000. Hypoglycaemia, liver ne-
crosis and perinatal death in mice lacking all isoforms of phosphoinositide
3-kinase p85 alpha. Nat. Genet. 26:379–382.
Gillham, H., M.C. Golding, R. Pepperkok, and W.J. Gullick. 1999. Intracellu-
lar movement of green fluorescent protein–tagged phosphatidylinositol
3-kinase in response to growth factor receptor signaling. J. Cell Biol.
146:869–880.
Gray, A., J. Van Der Kaay, and C.P. Downes. 1999. The pleckstrin homology
domains of protein kinase B and GRP1 (general receptor for phospho-
inositides-1) are sensitive and selective probes for the cellular detection
of phosphatidylinositol 3,4-bisphosphate and/or phosphatidylinositol
3,4,5-trisphosphate in vivo. Biochem. J. 344:929–936.
Griffiths, G. 1993. Fine Structure Immunocytochemistry. Springer-Verlag New
York Inc., Berlin. 459 pp.
Harpur, A.G., M.J. Layton, P. Das, M.J. Bottomley, G. Panayotou, P.C.
Driscoll, and M.D. Waterfield. 1999. Intermolecular interactions of the
p85alpha regulatory subunit of phosphatidylinositol 3-kinase. J. Biol.
Chem. 274:12323–12332.
JCB • VOLUME 170 • NUMBER 3 • 2005464
Huo, H., X. Guo, S. Hong, M. Jiang, X. Liu, and K. Liao. 2003. Lipid rafts/ca-
veolae are essential for insulin-like growth factor-1 receptor signaling
during 3T3-L1 preadipocyte differentiation induction. J. Biol. Chem.
278:11561–11569.
Inoue, G., B. Cheatham, R. Emkey, and C.R. Kahn. 1998. Dynamics of insulin
signaling in 3T3-L1 adipocytes. Differential compartmentalization and
trafficking of insulin receptor substrate (IRS)-1 and IRS-2. J. Biol.
Chem. 273:11548–11555.
James, S.R., C.P. Downes, R. Gigg, S.J. Grove, A.B. Holmes, and D.R.
Alessi. 1996. Specific binding of the Akt-1 protein kinase to phosphati-
dylinositol 3,4,5-trisphosphate without subsequent activation. Biochem. J.
315:709–713.
Joly, M., A. Kazlauskas, and S. Corvera. 1995. Phosphatidylinositol 3-kinase
activity is required at a postendocytic step in platelet-derived growth fac-
tor receptor trafficking. J. Biol. Chem. 270:13225–13230.
Jones, S.M., and A. Kazlauskas. 2001. Growth-factor-dependent mitogenesis re-
quires two distinct phases of signalling. Nat. Cell Biol. 3:165–172.
Kanai, F., H. Liu, S.J. Field, H. Akbary, T. Matsuo, G.E. Brown, L.C. Cantley,
and M.B. Yaffe. 2001. The PX domains of p47phox and p40phox bind to
lipid products of PI(3)K. Nat. Cell Biol. 3:675–678.
Kirwan, J.P., A. Varastehpour, M. Jing, L. Presley, J. Shao, J.E. Friedman, and
P.M. Catalano. 2004. Reversal of insulin resistance postpartum is linked
to enhanced skeletal muscle insulin signaling. J. Clin. Endocrinol.
Metab. 89:4678–4684.
Kulik, G., A. Klippel, and M.J. Weber. 1997. Antiapoptotic signalling by the insu-
lin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt.
Mol. Cell. Biol. 17:1595–1606.
Li, L., L.M. Gronning, P.O. Anderson, S. Li, K. Edvardsen, J. Johnston, D.
Kioussis, P.R. Shepherd, and P. Wang. 2004. Insulin induces SOCS-6
expression and its binding to p85 monomer of phosphoinositide 3-kinase,
resulting in improvement in glucose metabolism. J. Biol. Chem. 279:
34107–34114.
Mauvais-Jarvis, F., K. Ueki, D.A. Fruman, M.F. Hirshman, K. Sakamoto, L.J.
Goodyear, M. Iannacone, D. Accili, L.C. Cantley, and C.R. Kahn.
2002. Reduced expression of the murine p85alpha subunit of phospho-
inositide 3-kinase improves insulin signaling and ameliorates diabetes.
J. Clin. Invest. 109:141–149.
Nave, B.T., R.J. Haigh, A.C. Hayward, K. Siddle, and P.R. Shepherd. 1996.
Compartment-specific regulation of phosphoinositide 3-kinase by plate-
let-derived growth factor and insulin in 3T3-L1 adipocytes. Biochem. J.
318:55–60.
Nolte, R.T., M.J. Eck, J. Schlessinger, S.E. Shoelson, and S.C. Harrison. 1996.
Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and
its phosphopeptide complexes. Nat. Struct. Biol. 3:364–374.
Rameh, L.E., C.S. Chen, and L.C. Cantley. 1995. Phosphatidylinositol (3,4,5)P3
interacts with SH2 domains and modulates PI 3-kinase association with
tyrosine-phosphorylated proteins. Cell. 83:821–830.
Rohrschneider, L.R., J.F. Fuller, I. Wolf, Y. Liu, and D.M. Lucas. 2000. Structure,
function, and biology of SHIP proteins. Genes Dev. 14:505–520.
Rordorf-Nikolic, T., D.J. Van Horn, D. Chen, M.F. White, and J.M. Backer.
1995. Regulation of phosphatidylinositol 3-kinase by tyrosyl phospho-
proteins. Full activation requires occupancy of both SH2 domains in the
85-kDa regulatory subunit. J. Biol. Chem. 270:3662–3666.
Rotem-Yehudar, R., E. Galperin, and M. Horowitz. 2001. Association of insu-
lin-like growth factor 1 receptor with EHD1 and SNAP29. J. Biol. Chem.
276:33054–33060.
Saltiel, A.R., and C.R. Kahn. 2001. Insulin signalling and the regulation of glu-
cose and lipid metabolism. Nature. 414:799–806.
Songyang, Z., S.E. Shoelson, M. Chaudhuri, G. Gish, T. Pawson, W.G. Haser,
F. King, T. Roberts, S. Ratnofsky, R.J. Lechleider, et al. 1993. SH2 do-
mains recognize specific phosphopeptide sequences. Cell. 72:767–778.
Terauchi, Y., Y. Tsuji, S. Satoh, H. Minoura, K. Murakami, A. Okuno, K. Inu-
kai, T. Asano, Y. Kaburagi, K. Ueki, et al. 1999. Increased insulin sensi-
tivity and hypoglycaemia in mice lacking the p85 alpha subunit of phos-
phoinositide 3-kinase. Nat. Genet. 21:230–235.
Toomre, D., and D.J. Manstein. 2001. Lighting up the cell surface with evanes-
cent wave microscopy. Trends Cell Biol. 11:298–303.
Tureckova, J., E.M. Wilson, J.L. Cappalonga, and P. Rotwein. 2001. Insulin-like
growth factor-mediated muscle differentiation: collaboration between
phosphatidylinositol 3-kinase-Akt-signaling pathways and myogenin.
J. Biol. Chem. 276:39264–39270.
Ueki, K., P. Algenstaedt, F. Mauvais-Jarvis, and C.R. Kahn. 2000. Positive and
negative regulation of phosphoinositide 3-kinase-dependent signaling
pathways by three different gene products of the p85alpha regulatory
subunit. Mol. Cell. Biol. 20:8035–8046.
Ueki, K., D.A. Fruman, S.M. Brachmann, Y.H. Tseng, L.C. Cantley, and C.R.
Kahn. 2002a. Molecular balance between the regulatory and catalytic sub-
units of phosphoinositide 3-kinase regulates cell signaling and survival.
Mol. Cell. Biol. 22:965–977.
Ueki, K., C.M. Yballe, S.M. Brachmann, D. Vicent, J.M. Watt, C.R. Kahn, and
L.C. Cantley. 2002b. Increased insulin sensitivity in mice lacking
p85beta subunit of phosphoinositide 3-kinase. Proc. Natl. Acad. Sci.
USA. 99:419–424.
Ueki, K., D.A. Fruman, C.M. Yballe, M. Fasshauer, J. Klein, T. Asano, L.C.
Cantley, and C.R. Kahn. 2003. Positive and negative roles of p85 alpha
and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin
signaling. J. Biol. Chem. 278:48453–48466.
Varnai, P., K.I. Rother, and T. Balla. 1999. Phosphatidylinositol 3-kinase-
dependent membrane association of the Bruton’s tyrosine kinase pleck-
strin homology domain visualized in single living cells. J. Biol. Chem.
274:10983–10989.
Virkamaki, A., K. Ueki, and C.R. Kahn. 1999. Protein-protein interaction in
insulin signaling and the molecular mechanisms of insulin resistance.
J. Clin. Invest. 103:931–943.
White, M.F. 1998. The IRS-signaling system: a network of docking proteins that
mediate insulin and cytokine action. Recent Prog. Horm. Res. 53:119–138.
Yu, J., C. Wjasow, and J.M. Backer. 1998a. Regulation of the p85/p110alpha
phosphatidylinositol 3-kinase. Distinct roles for the n-terminal and
c-terminal SH2 domains. J. Biol. Chem. 273:30199–30203.
Yu, J., Y. Zhang, J. McIlroy, T. Rordorf-Nikolic, G.A. Orr, and J.M. Backer.
1998b. Regulation of the p85/p110 phosphatidylinositol 3-kinase: stabi-
lization and inhibition of the p110alpha catalytic subunit by the p85 reg-
ulatory subunit. Mol. Cell. Biol. 18:1379–1387.
Zacharias, D.A. 2002. Sticky caveats in an otherwise glowing report: oligo-
merizing fluorescent proteins and their use in cell biology. Sci. STKE.
2002:PE23.
